Within this study a total of 90 respondents answered a survey tailored to melanoma patients, healthy respondents, and health care providers on valuation of a new treatment option, the anti-CTLA4-antibody ipilimumab, with marginal benefit, i.e. a low response rate, frequent side effects and a modest prolongation of median overall survival of 2 months. This evidence concerns the gene CTLA4 and melanoma.